Impressive Sales Growth and Operational Advances at Novo Nordisk
During the recent financial period covering the first nine months of 2025, Novo Nordisk showcased remarkable sales performance with a notable increase of 12% in Danish kroner and 15% at constant exchange rates (CER). This growth signifies the company's resilience and adaptability in the fast-paced healthcare market, allowing it to continue developing its diverse range of therapeutic solutions.
Financial Highlights and Impact of Restructuring
Despite facing approximately DKK 9 billion in one-off restructuring costs aimed at improving overall operational efficiency as part of a larger transformation strategy, the company's operating profit still rose by 5% in Danish kroner, reaching DKK 95.9 billion, and demonstrating a significant 10% increase under constant exchange rates. Interestingly, without these costs, the operating profit could have surged by 15% in Danish kroner and 21% at CER.
Sales Dynamics Across Global Operations
The sales figures revealed a strong performance in U.S. operations, increasing by 12% in Danish kroner and 15% at CER, benefiting from favorable gross-to-net sales adjustments. Meanwhile, sales in International Operations advanced by 13% in Danish kroner and 16% at CER, showing the company's extensive reach and growth potential worldwide.
Breakthrough Developments in Diabetes and Obesity Care
In the diabetes and obesity sector, Novo Nordisk witnessed a sales boost of 12%, totaling DKK 215.7 billion at reported rates (15% at CER). This growth was primarily driven by a staggering 37% rise in obesity care sales, reaching DKK 59.9 billion (41% at CER), paired with solid gains in GLP-1 diabetes medications, which climbed 7% in Danish kroner and 10% at CER. Additionally, the company reported a 10% improvement in its rare disease segment, highlighting its dedication to addressing a variety of health challenges.
Regulatory Progress and Strategic Acquisitions
Advancing in research and development, Novo Nordisk celebrated the approval granted by the U.S. FDA for Wegovy for treating MASH, further solidifying its pivotal role in chronic disease management. Additionally, the anticipated acquisition of Akero Therapeutics, Inc. for its phase 3 FGF21 analogue in MASH represents a strategic step towards enhancing Novo Nordisk's offerings in this market. Furthermore, the company initiated cagrilintide's phase 3 development, aiming to establish it as the first dedicated amylin monotherapy for effective weight management.
Looking Beyond 2025: Adjusted Growth Expectations
As the company looks ahead, it has modified its full-year 2025 outlook, forecasting sales growth between 8% to 11% at constant exchange rates and operating profit growth between 4% to 7%, which accounts for the ongoing implications of its comprehensive transformation. This adjustment reflects a more conservative outlook stemming from reduced growth projections for its GLP-1 treatment line within diabetes and obesity.
Board of Directors and Organizational Development
In October, an extraordinary general meeting was announced to convene on November 14, 2025, enabling the election of new members to the Board of Directors. This organizational renewal can further support Novo Nordisk’s strategies and operational goals moving forward.
Conclusion: A Focus on Sustainable Growth
Mike Doustdar, president and CEO, emphasized the importance of the company's transformation, stating, "Our company-wide transformation has already driven operational efficiencies, and we have a renewed focus that can deliver a range of potential treatment options that will serve millions more patients, mainly in obesity. While we delivered robust sales growth in the first nine months of 2025, the lower growth expectations for our GLP-1 treatments have led to a narrowing of our guidance. We aim to accelerate on all fronts to be able to compete better in dynamic and increasingly competitive markets." His remarks underline Novo Nordisk's commitment to not just maintaining but enhancing its competitive edge within the healthcare sector.
Frequently Asked Questions
What are the recent sales growth figures for Novo Nordisk?
In the first nine months of 2025, Novo Nordisk experienced a 12% increase in sales reported in Danish kroner and a 15% rise at constant exchange rates.
What challenges is Novo Nordisk currently facing?
The company is facing challenges due to one-off restructuring costs of approximately DKK 9 billion and a lowered growth outlook for its GLP-1 treatment segment within diabetes and obesity care.
What significant acquisitions has Novo Nordisk announced?
Novo Nordisk has agreed to acquire Akero Therapeutics, Inc., enhancing its pipeline with potential treatment options in MASH.
How has Novo Nordisk performed in the obesity care market?
Sales in the obesity care market soared by 37% in Danish kroner, demonstrating the company's strong positioning in this rapidly growing segment.
When is Novo Nordisk's next extraordinary general meeting?
The extraordinary general meeting is scheduled for November 14, 2025, where new members of the Board of Directors will be elected.
